[1] |
国家心血管病中心. 中国心血管健康与疾病报告2021[M]. 北京: 科学出版社, 2022.
|
[2] |
MARCOVINA S M, KOSCHINSKY M L. Lipoprotein(a) as a risk factor for coronary artery disease[J]. Am J Cardiol, 1998, 82(12A):57U-66U.
DOI
PMID
|
[3] |
中国成人血脂异常防治指南修订联合委员会. 中国成人血脂异常防治指南(2016年修订版)[J]. 中华心血管病杂志, 2016, 44(10):833-853.
|
[4] |
KRONENBERG F, MORA S, STROES E S G, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis:a European Atherosclerosis Society consensus statement[J]. Eur Heart J, 2022, 43(39):3925-3946.
DOI
URL
|
[5] |
WITZTUM J L, GINSBERG H N. Lipoprotein(a):coming of age at last[J]. J Lipid Res, 2016, 57(3):336-339.
DOI
URL
|
[6] |
MACH F, BAIGENT C, CATAPANO A L, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias:lipid modification to reduce cardiovascular risk[J]. Eur Heart J, 2020, 41(1):111-188.
DOI
URL
|
[7] |
ARNETT D K, BLUMENTHAL R S, ALBERT M A, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease:a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines[J]. Circulation, 2019, 140(11):e596-e646.
|
[8] |
NORDESTGAARD B G, LANGSTED A. Lipoprotein(a) as a cause of cardiovascular disease:insights from epidemiology,genetics,and biology[J]. J Lipid Res, 2016, 57(11):1953-1975.
DOI
URL
|
[9] |
印中鹏, 吴嘉, 汪俊军. 慢性肾脏疾病患者血清脂蛋白(a)颗粒浓度与质量浓度检测结果的差异比较[J]. 中华检验医学杂志, 2021, 44(7):596-601.
|
[10] |
KAMSTRUP P R. Lipoprotein(a) and cardiovascular disease[J]. Clin Chem, 2021, 67(1):154-166.
DOI
PMID
|
[11] |
王吉耀, 葛均波, 邹和建, 等. 实用内科学(第16版)[M]. 北京: 人民卫生出版社, 2022.
|
[12] |
中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗指南(2022年版)[J]. 中华肝脏病杂志, 2022, 30(4):367-388.
|
[13] |
中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2020年版)[J]. 中华糖尿病杂志, 2021, 13(4):315-409.
|
[14] |
STEVENS P E, LEVIN A, Kidney Disease:Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members. Evaluation and management of chronic kidney disease:synopsis of the kidney disease:improving global outcomes 2012 clinical practice guideline[J]. Ann Intern Med, 2013, 158(11):825-830.
DOI
URL
|
[15] |
STEYRER E, DUROVIC S, FRANK S, et al. The role of lecithin:cholesterol acyltransferase for lipoprotein(a) assembly. Structural integrity of low density lipoproteins is a prerequisite for Lp(a) formation in human plasma[J]. J Clin Invest, 1994, 94(6):2330-2340.
DOI
URL
|
[16] |
冯仁丰. 脂蛋白(a)检测的标准化[J]. 检验医学, 2017, 32(7):555-560.
|
[17] |
MCCONNELL J P, GUADAGNO P A, DAYSPRING T D, et al. Lipoprotein(a) mass:a massively misunderstood metric[J]. J Clin Lipidol, 2014, 8(6):550-553.
DOI
URL
|
[18] |
SENTÍ M, PEDRO-BOTET J, RUBIÉS-PRAT J, et al. Interrelationship of triglyceride-rich lipoproteins,serum lipoprotein(a) concentration and apolipoprotein(a) size[J]. Scand J Clin Lab Invest, 1996, 56(4):311-318.
DOI
URL
|
[19] |
MARCOVINA S M, ALBERS J J. Lipoprotein(a) measurements for clinical application[J]. J Lipid Res, 2016, 57(4):526-537.
DOI
URL
|
[20] |
KAMSTRUP P R, BENN M, TYBJAERG-HANSEN A, et al. Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population:the Copenhagen City Heart Study[J]. Circulation, 2008, 117(2):176-184.
DOI
URL
|
[21] |
FEELY J, BARRY M, KEELING P W, et al. Lipoprotein(a) in cirrhosis[J]. BMJ, 1992, 304(6826):545-546.
PMID
|
[22] |
LANGSTED A, KAMSTRUP P R, NORDESTGAARD B G. High lipoprotein(a) and high risk of mortality[J]. Eur Heart J, 2019, 40(33):2760-2770.
DOI
PMID
|
[23] |
TSIMIKAS S, FAZIO S, VINEY N J, et al. Relationship of lipoprotein(a) molar concentrations and mass according to lipoprotein(a) thresholds and apolipoprotein(a) isoform size[J]. J Clin Lipidol, 2018, 12(5):1313-1323.
DOI
PMID
|